Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of high-dose post-transplantation cyclophosphomide as
graft-versus-host disease (GVHD) prophylaxis after allogeneic stem cell transplantation in
patients with different risk of GVHD. The risk-adapted strategy involves using single-agent
cyclophosphomide in recipients of matched bone marrow graft, and combining cyclophosphomide
with tacrolimus and mycophenolate mofetil in recipients of matched peripheral blood stem
cells and mismatched bone marrow.
Phase:
Phase 2
Details
Lead Sponsor:
Ivan S Moiseev St. Petersburg State Pavlov Medical University